|
|
| Industry Report |
| Revenue of first quarter 2012 |
| ADOCIA, a biotechnology company specialized in the development of best-in-class medicines with already-approved therapeutic proteins, announces today revenues of EUR 1.2 million for the first quarter of 2012 compared to EUR 0.6 million for the same quarter last year. |
|
|
|
 |
|
|
|
| Press Releases |
| Adocia reports positive phase II clinical results for the treatment of diabetic foot ulcer |
| Read more... |
| Novasep’s outstanding results in scale-up and biomanufacturing of Apo-A1 acknowledged by Cerenis at BioProcess International Conference |
| Read more... |
| Immutep and Lonza sign agreement for cell line selection, cell banking and process development of ImmuFact(R) IMP321 |
| Read more... |
| According to PricewaterhouseCoopers, the Indian pharmaceutical market is expected to grow from US$11 billion to US$74 billion by 2020 |
| Read more... |
|
| News |
| AstraZeneca to acquire Ardea Biosciences for $1 billion |
| Read more... |
| Key protein responsible for controlling nerve cell protection |
| Read more... |
| Rosetta wins European patent covering core element of microRNA technology |
| Read more... |
| Women don't receive the same treatment as men for heart disease the world-over |
| Read more... |
|
| Research Insight |
| Antares, Watson Pharmaceuticals launch Gelnique 3% in US |
| Read more... |
| Meridian, Teva settle epinephrine auto-injector pending patent litigation |
| Read more... |
| Affymax, Takeda launch OMONTYS injection in US |
| Read more... |
| Watson introduces generic version of Fortamet |
| Read more... |
|
|
| Techno Trend |
Oracle Introduces Oracle Health Sciences InForm Global Trial Management 5.5
|
| Read more... |
| |
 |
|
  |
| |
| UPLOAD YOUR CONTENT |
 |
| |
|
| |
Advertise in Our Next Issue
Contact Soumya.
soumya@worldpharmatoday.com
(or)
 |
|
